FDA's Computer Software Assurance (CSA) Guidance issued on February 3, 2026 Explained
Understanding Regulatory Intent, Risk-Based Assurance, and Practical Implications for Production and Quality Systems
Introduction
What FDA Says
FDA is issuing this guidance to provide recommendations on Computer Software Assurance for computers and automated data processing systems used as part of medical device production or quality management systems. The guidance describes a risk-based approach for establishing confidence in software used within these processes.
FDA's Intent
FDA is making clear that it is not creating a new validation requirement. Rather, it is explaining a modernized approach for demonstrating that software performs as intended. The Agency is attempting to shift industry attention from documentation quantity toward assurance effectiveness.
FDA appears to recognize that many companies have built validation programs that exceed what is necessary to establish confidence in software performance. The intent is to encourage manufacturers to focus on activities that improve quality and reduce risk rather than activities that primarily generate documentation. ,
Examples
Software falling within the scope of the guidance may include:
- Manufacturing Execution Systems (MES)
- Quality Management Systems (QMS)
- CAPA management software
- Complaint handling systems
- Production data collection systems
- Electronic record management systems
All of these systems may require assurance activities, but the level of assurance should correspond to risk and intended use.
Inspection Implications
Inspectors may expect firms to explain:
- How they define software assurance
- How they establish confidence in software performance
- How their assurance process connects to risk
Organizations that continue to equate compliance solely with document volume may have difficulty explaining how assurance activities contribute to system confidence.
Background
What FDA Says
The guidance explains the rationale for adopting Computer Software Assurance and describes the evolution from traditional computer software validation approaches toward more risk-based methods.
FDA's Intent
FDA appears to be acknowledging that software technology has evolved significantly while many validation programs have not. The Agency recognizes that extensive scripted testing and documentation may create burdens without proportionate improvements in software quality or patient safety.
The intent is to promote adoption of newer technologies and more efficient quality practices while maintaining confidence in software used within regulated operations. ,
Examples
Challenges frequently seen under traditional validation programs include:
- Large validation reports for low-risk systems
- Repetitive scripted testing
- Lengthy implementation timelines
- Resource-intensive change management activities
These practices may consume substantial resources while contributing little additional confidence in system performance.
Inspection Implications
Inspectors may look for evidence that an organization understands the rationale behind its assurance activities rather than merely following legacy validation practices.
Organizations should be able to explain why specific activities were chosen and how they support confidence in software performance.
Scope
What FDA Says
The guidance applies to software used in production activities and quality management system activities. This includes computers and automated data processing systems used as part of manufacturing and quality operations. ,
FDA's Intent
FDA is attempting to ensure that firms apply a consistent assurance philosophy across systems that support regulated activities. The focus is not on software category but rather on the function the software performs within production and quality processes.
The Agency appears to be encouraging organizations to evaluate software based on intended use and impact rather than on whether the software is internally developed, purchased, cloud-based, or commercially available. ,
Examples
Systems potentially within scope include:
- MES platforms
- Training management systems
- Supplier quality systems
- Audit management systems
- Electronic batch record systems
- Complaint management software
- Laboratory information management systems
Inspection Implications
Organizations should have a defensible rationale for determining which systems are included within their Computer Software Assurance program and why.
Inspectors may question inconsistencies in the treatment of systems that support similar regulated functions.
Definitions
What FDA Says
The guidance provides definitions for key concepts used throughout the document, creating a common framework for discussing assurance activities and decision-making.
FDA's Intent
FDA is establishing a common language that supports consistent interpretation of the guidance. Definitions reduce the likelihood that assurance activities will be based on differing assumptions or interpretations.
The Agency appears to recognize that many disagreements regarding software validation originate from differing understandings of terminology.
Examples
Terms such as:
- Intended use
- Risk
- Assurance
- Objective evidence
serve as foundational concepts throughout the remainder of the guidance.
Inspection Implications
Inspectors may expect terminology used in procedures, risk assessments, and assurance records to align with the concepts presented in the guidance.
A consistent vocabulary often demonstrates procedural maturity and organizational understanding.
Computer Software Assurance
What FDA Says
FDA describes Computer Software Assurance as a risk-based approach used to establish confidence that software performs as intended. Assurance activities should be appropriate for the software's intended use and associated risk.
FDA's Intent
This is the central message of the guidance.
FDA is attempting to move organizations away from treating software assurance as a document-generation process and toward treating it as a quality assurance activity focused on evidence and risk evaluation.
The Agency appears to be emphasizing confidence in performance rather than compliance through documentation volume. ,
Examples
Evidence supporting assurance might include:
- Test results
- Screenshots
- Session records
- Automated test logs
- User acceptance evidence
- Configuration reviews
The specific form of evidence may vary according to risk.
Inspection Implications
Inspectors may focus on whether assurance activities are capable of demonstrating that software performs as intended.
The organization's rationale for confidence may be more important than the amount of documentation generated.
Computer Software Assurance Risk Framework
What FDA Says
FDA presents a risk framework used to determine the level of assurance necessary for software functions based on their potential impact.
FDA's Intent
FDA is encouraging firms to direct resources toward areas where software failure could affect product quality, patient safety, process control, data integrity, or compliance.
The Agency appears to be discouraging uniform validation strategies that treat all functions equally regardless of risk. ,
Examples
Higher-impact functions may include:
- Release decisions
- Process parameter control
- Electronic quality record creation
- Acceptance criteria calculations
Lower-impact functions may include:
- Notifications
- Scheduling activities
- Administrative reporting
Inspection Implications
Inspectors may expect a clear connection between:
- Risk evaluation
- Assurance strategy
- Objective evidence
An inability to explain this connection could suggest weaknesses in the assurance process.
Identifying Intended Use
What FDA Says
FDA identifies intended use as a foundational element within the risk framework and assurance process.
FDA's Intent
FDA wants organizations to understand what a system is expected to accomplish before attempting to determine risk or define testing activities.
The Agency appears to view intended use as the starting point for all subsequent assurance decisions.
Examples
An intended use statement may describe:
- Process supported
- Users
- Inputs
- Outputs
- Quality decisions supported
Examples include software intended to:
- Generate device history records
- Manage employee training
- Control manufacturing parameters
- Route quality events
Inspection Implications
Inspectors may examine whether assurance activities trace back to clearly defined intended use statements.
Weak or overly generic intended use statements may undermine subsequent risk assessments.
Determining the Risk-Based Approach
What FDA Says
FDA recommends determining assurance efforts using a risk-based evaluation of software functions and their potential impact.
FDA's Intent
FDA is attempting to shift thinking away from software complexity and toward the consequences of software failure.
The Agency appears to be emphasizing outcome-based risk assessment rather than technology-based risk assessment.
Examples
Questions that may drive risk determination include:
- Could failure affect quality decisions?
- Could failure affect released product?
- Could failure compromise records?
- Could failure impact regulatory compliance?
Inspection Implications
Inspectors may evaluate whether risk rankings are supported by a credible assessment of potential consequences.
Organizations should be prepared to explain risk decisions logically and consistently.
Production or Quality Management System Software Changes
What FDA Says
FDA discusses evaluating software changes and determining appropriate assurance activities for modified systems and functions.
FDA's Intent
FDA recognizes that software systems evolve continuously and wants organizations to assess changes according to impact and risk rather than applying identical revalidation activities to every change.
The Agency appears to support targeted reassessment where justified by risk.
Examples
Changes may include:
- Vendor patches
- Configuration changes
- Workflow modifications
- Interface updates
- New functionality
Not all changes necessarily require identical levels of assurance.
Inspection Implications
Inspectors may review change assessments to determine whether the organization evaluated the impact of modifications before implementing them.
Determining the Appropriate Assurance Activities
What FDA Says
FDA states that organizations should select assurance activities that establish confidence in software performance while remaining appropriate for the intended use and associated risk. ,
FDA's Intent
FDA is introducing flexibility in how software assurance may be accomplished.
The Agency appears to be making clear that meaningful evidence can be generated through various approaches, not solely through scripted testing.
Examples
Potential assurance activities include:
- Scripted testing
- Unscripted testing
- Exploratory testing
- Automated testing
- User acceptance testing
Each may be appropriate depending on the risk and purpose being evaluated.
Inspection Implications
Inspectors may focus on whether the chosen activities were suitable for establishing confidence in performance rather than whether a particular testing methodology was used.
Additional Considerations for Assurance Activities
What FDA Says
FDA discusses factors that may influence assurance decisions beyond basic functionality and testing approaches.
FDA's Intent
FDA appears to be encouraging firms to consider the broader operational environment in which software is used.
The Agency recognizes that software performance depends not only on functionality but also on users, processes, interfaces, and operating conditions.
Examples
Relevant considerations may include:
- User roles
- System interfaces
- Data transfers
- Operational workflows
- Configuration settings
Inspection Implications
Inspectors may evaluate whether assurance activities adequately reflected actual business use conditions.
Establishing the Appropriate Record
What FDA Says
FDA discusses maintaining records that support assurance conclusions and demonstrate confidence that software performs as intended.
FDA's Intent
FDA is attempting to separate documentation quality from documentation quantity.
The Agency appears to want records that clearly explain what was done, why it was done, what was observed, and what conclusions were reached.
Examples
Records may include:
- Risk assessments
- Test notes
- Test execution records
- Screenshots
- Review approvals
- Automated test outputs
- Deviation documentation
Inspection Implications
Inspectors are likely to evaluate whether records provide a coherent and defensible explanation for the organization's assurance conclusions.
Well-structured records should allow an independent reviewer to understand the basis for confidence in software performance without requiring excessive supporting documentation.